A phase 3 trial evaluates the efficacy of mezigdomide plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/mezigdomide-triplet-improves-pfs-r-r-multiple-myeloma-2026a1000lzr?src=rss
Author :
Publish date : 2026-06-29 12:02:00
Copyright for syndicated content belongs to the linked Source.
